MedTrace Logo

A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials

NCT06172374 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-05-11

No results posted yet for this study

Summary

Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.

Conditions

  • Primary Ciliary Dyskinesia

Interventions

GENETIC

Sano Genetics Testing Kit

Genetic testing spit collection tubes for DNA testing

Sponsors & Collaborators

  • Sano Genetics

    collaborator INDUSTRY

  • Reverba

    collaborator UNKNOWN

  • ReCode Therapeutics

    lead INDUSTRY

Principal Investigators

  • John G. Matthews, MBBS, MRCP, PhD · ReCode Therapeutics, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2025-04-30
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06172374 on ClinicalTrials.gov